Collectively, this study provides a therapeutic strategy for PAD disease by EC-target delivery of S1pr2-siRNA for inhibition of S1pr2 expression via improving post-ischemic angiogenesis and tissue repair. This evidence concerns the gene S1PR2 and peripheral arterial disease.